Hsiri Therapeutics, LLC


Hsiri is dedicated to creating novel cures for serious infectious diseases, including non-tuberculous mycobacterial diseases and diseases caused by gram-negative bacteria such as Pseudomonas aeruginosa and Acinetobacter baumanii.

Significant Achievements: 
  • Developed a drug (HT-07) to fight multi-drug resistant bacteria, including E. coli and acinetobacter, which causes nearly 80% of reported infections.
  • Submitted additional grant applications to continue development and testing of HT-07 drug.
  • Successfully demonstrated in vitro that drug HT-10 effectively attacks highly resistant, systemic and life threatening diseases.
  • Partnering with the National Institute of Allergy and Infectious Diseases (NIAID) to develop and test Hsiri products (primarily HT-06, HT-07, HT-10) and to treat  tuberculosis.
Key Needs: 
  • Ongoing funding to cover research and development, and general and administrative expenses, as the significant portfolio of pharmaceutical assets approach FDA IND enabling studies.
Public Mentions: 
  • Received a Small Business Innovation award (SBIR grant) by the NIH to develop new treatments in drug resistant bacterial infections.
Funding: 
  • SBIR funding in 2017 is anticipated. p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 11.0px Calibri} span.s1 {font-kerning: none}
Partnerships: 
  • Significant scientific support from the NIH in the development of the Hsiri anti-Tuberculosis drugs.